The ASH Annual Meeting virtual platform opens on Wednesday, December 4, 2024, to all attendees. Most sessions offered in San Diego will be broadcast simultaneously on the virtual platform. Once a session takes
63rd ASH Annual Meeting and ExpositionCheryl Lai
04:30 PM - 05:45 PM |精准医学中的种族与血统因素:多维度解析与前瞻性探讨。 66th ASH Annual Meeting and Exposition 责任编辑:肿瘤资讯-kaylee
ASH 2025 - The 67th American Society of Hematology Annual Meeting & Exposition 时间/Date: December, 2025 会场/Venue: Orlando, Florida, USA ASH Annual Meeting & Exposition——The premier event in malignant and non-malignant hematology 以下为往届会议信息,仅供参考! ASH 2024 - The 66th American S...
Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. The2024 American Society of Hematology (ASH) Annual Meeting and Expositionwas held in San Diego on December ...
products for the treatment of cancer, today announced the presentation of CD38-SADA in Non-Hodgkin Lymphoma (NHL) preclinical data and trial in progress posters at the 66thAmerican Society of Hematology(ASH) Annual Meeting & Exposition being held onDecember 7–10, 2024, inSan Diego,...
AstraZeneca advances its ambition to redefine cancer care with new data across its industry-leading and diverse pipeline in hematology at the 66thAmerican Society of Hematology (ASH) Annual Meeting and Exposition December 7-10, 2024. A total of 57 abstracts will featur...
66th American Society of Hematology Annual Meeting and Exposition (ASH 2024) Booth #105NinaMaria, living with thalassemia Agios ASH 2024 Data Room Agios is presenting new data on mitapivat and tebapivat (AG-946), the company’s two PK activators, at ASH 2024. Key presentations and publica...
The66th ASH Annual Meeting and Expositiontook place from Saturday, December 7 to Tuesday, December 10 in San Diego, California. You can read ourcoverage here. Lin:Absolutely. Earlier this year, there was published a large meta-analysis of...
6, 2024-- GlycoMimetics, Inc. (Nasdaq: GLYC) today announced that data from multiple clinical trials studying uproleselan in patients with acute myeloid leukemia (AML) have been accepted for presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Expositio...